These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 25272281)

  • 21. Intranasal naloxone for treatment of opioid overdose.
    Med Lett Drugs Ther; 2014 Mar; 56(1438):21-2. PubMed ID: 24662159
    [No Abstract]   [Full Text] [Related]  

  • 22. Findings and lessons learnt from implementing Australia's first health service based take-home naloxone program.
    Chronister KJ; Lintzeris N; Jackson A; Ivan M; Dietze PM; Lenton S; Kearley J; van Beek I
    Drug Alcohol Rev; 2018 May; 37(4):464-471. PubMed ID: 27071354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Do heroin overdose patients require observation after receiving naloxone?
    Willman MW; Liss DB; Schwarz ES; Mullins ME
    Clin Toxicol (Phila); 2017 Feb; 55(2):81-87. PubMed ID: 27849133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intranasal naloxone soon to become part of evolving clinical practice around opioid overdose prevention.
    Dietze P; Cantwell K
    Addiction; 2016 Apr; 111(4):584-6. PubMed ID: 26995168
    [No Abstract]   [Full Text] [Related]  

  • 25. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal in Russian cities.
    Coffin PO; Sullivan SD
    J Med Econ; 2013 Aug; 16(8):1051-60. PubMed ID: 23730942
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overdose rescues by trained and untrained participants and change in opioid use among substance-using participants in overdose education and naloxone distribution programs: a retrospective cohort study.
    Doe-Simkins M; Quinn E; Xuan Z; Sorensen-Alawad A; Hackman H; Ozonoff A; Walley AY
    BMC Public Health; 2014 Apr; 14():297. PubMed ID: 24684801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Opioid overdose education and naloxone distribution: Development of the Veterans Health Administration's national program.
    Oliva EM; Christopher MLD; Wells D; Bounthavong M; Harvey M; Himstreet J; Emmendorfer T; Valentino M; Franchi M; Goodman F; Trafton JA;
    J Am Pharm Assoc (2003); 2017; 57(2S):S168-S179.e4. PubMed ID: 28292502
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: Challenges and innovations responding to a dynamic epidemic.
    Fairbairn N; Coffin PO; Walley AY
    Int J Drug Policy; 2017 Aug; 46():172-179. PubMed ID: 28687187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Opioid overdose prevention and naloxone rescue kits: what we know and what we don't know.
    Kerensky T; Walley AY
    Addict Sci Clin Pract; 2017 Jan; 12(1):4. PubMed ID: 28061909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development and process evaluation of an educational intervention for overdose prevention and naloxone distribution by general practice trainees.
    Klimas J; Egan M; Tobin H; Coleman N; Bury G
    BMC Med Educ; 2015 Nov; 15():206. PubMed ID: 26590066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The implementation of a naloxone rescue program in university students.
    Panther SG; Bray BS; White JR
    J Am Pharm Assoc (2003); 2017; 57(2S):S107-S112.e2. PubMed ID: 28063773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The social logic of naloxone: Peer administration, harm reduction, and the transformation of social policy.
    Faulkner-Gurstein R
    Soc Sci Med; 2017 May; 180():20-27. PubMed ID: 28315595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Take-home emergency naloxone to prevent heroin overdose deaths after prison release: rationale and practicalities for the N-ALIVE randomized trial.
    Strang J; Bird SM; Parmar MK
    J Urban Health; 2013 Oct; 90(5):983-96. PubMed ID: 23633090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identifying gaps in the implementation of naloxone programs for laypersons in the United States.
    Lambdin BH; Zibbell J; Wheeler E; Kral AH
    Int J Drug Policy; 2018 Feb; 52():52-55. PubMed ID: 29232604
    [No Abstract]   [Full Text] [Related]  

  • 35. Saved by the nose: bystander-administered intranasal naloxone hydrochloride for opioid overdose.
    Doe-Simkins M; Walley AY; Epstein A; Moyer P
    Am J Public Health; 2009 May; 99(5):788-91. PubMed ID: 19363214
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of Take-Home Naloxone and Opioid Overdose Reversals Performed by Patients in an Opioid Treatment Program.
    Katzman JG; Takeda MY; Greenberg N; Moya Balasch M; Alchbli A; Katzman WG; Salvador JG; Bhatt SR
    JAMA Netw Open; 2020 Feb; 3(2):e200117. PubMed ID: 32101312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Challenges with take-home naloxone in reducing heroin mortality: a review of fatal heroin overdose cases in Victoria, Australia.
    Stam NC; Gerostamoulos D; Smith K; Pilgrim JL; Drummer OH
    Clin Toxicol (Phila); 2019 May; 57(5):325-330. PubMed ID: 30451007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Community-based opioid overdose prevention programs providing naloxone - United States, 2010.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Feb; 61(6):101-5. PubMed ID: 22337174
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence-Based Guidelines for EMS Administration of Naloxone.
    Williams K; Lang ES; Panchal AR; Gasper JJ; Taillac P; Gouda J; Lyng JW; Goodloe JM; Hedges M
    Prehosp Emerg Care; 2019; 23(6):749-763. PubMed ID: 30924736
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of Opioid Overdose Knowledge (OOKS) and Attitudes (OOAS) Scales for take-home naloxone training evaluation.
    Williams AV; Strang J; Marsden J
    Drug Alcohol Depend; 2013 Sep; 132(1-2):383-6. PubMed ID: 23453260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.